Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
With
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ages ≥18 years，ECOG ≤ 2，Estimated survival time \> 3 months
Histologically or Cytologically confirmed metastatic pancreatic adenocarcinoma
Based on Response Evaluation Criteria In Solid Tumors (RECIST1.1), there should be at least one measurable lesion
Patients have never received systematical anti-cancer therapy
Laboratory examination meets the following requirements:White blood cell (WBC) ≥3.0×109/L; absolute neutrophil count (ANC) ≥1.5×109/L; Hemoglobin (HB) ≥90g/L; platelet count(PLT) ≥75×109/L; Total bilirubin (TBIL) ≤1.5× normal upper limit (ULN); Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN, if accompanied by liver metastasis, ALT and AST≤5×ULN; Serum creatinine (Cr) ≤1×ULN or creatinine clearance (CCr)≥50ml/min;
Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) \> 50%
Patients of childbearing age should take appropriate protective measures before enrollment and during the trial
Volunteer to join the study, sign the informed consent, have good compliance, and cooperate with follow-up
Ability to follow the study protocol and follow-up procedures.
You may not be if
Patients have ever received any systematical anti-cancer therapy in the past
Patients who participated in other clinical trials in the past 4 weeks
According to the investigator, patients who surgically available or potentially treatable(Patients who voluntarily give up surgical treatment can be enrolled after evaluation by the investigator)
Patients with moderate ascites requiring drainage
Patients with CNS metastases and/or carcinomatous meningitis
Patients with history of other primary malignancies except: 1) complete remission before enrollment for at least 2 years and requiring no additional treatment during the study period; 2) Adequately treated non-melanoma skin cancer or lentiform malignancy with no evidence of disease recurrence; 3) Adequately treated carcinoma in situ with no evidence of disease recurrence;
Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs
Patients with bleeding tendency.
Pregnant or lactating women.
Drug abuse, clinical or psychological or social factors that impact informed consent or the conduct of the study
Patients who may be allergic to PD-1 monoclonal antibody, anlotinib, albumin-bound paclitaxel and gemcitabine
